Advanced search
Publication Cover
Renal Failure Volume 46, 2024 - Issue 2
Submit an article Journal homepage
355
Views
0
CrossRef citations to date
0
Altmetric
Acute Kidney Injury

SGLT2 inhibitor dapagliflozin reduces proximal tubular cell damage biomarkers in patients with acute heart failure

Pongsathorn GojaseniDivision of Nephrology, Department of Medicine, Bhumibol Adulyadej Hospital, Directorate of Medical Services, Royal Thai Air Force, Bangkok, ThailandCorrespondence[email protected]
View further author information
,
Jananya WattanakulDivision of Nephrology, Department of Medicine, Bhumibol Adulyadej Hospital, Directorate of Medical Services, Royal Thai Air Force, Bangkok, ThailandView further author information
,
Anan ChuasuwanDivision of Nephrology, Department of Medicine, Bhumibol Adulyadej Hospital, Directorate of Medical Services, Royal Thai Air Force, Bangkok, ThailandView further author information
&
Anutra ChittinandanaDivision of Nephrology, Department of Medicine, Bhumibol Adulyadej Hospital, Directorate of Medical Services, Royal Thai Air Force, Bangkok, ThailandView further author information
Article: 2373275 | Received 12 Apr 2024, Accepted 21 Jun 2024, Published online: 05 Jul 2024

References

  • Nuffield Department of Population Health Renal Studies Group. SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–1801.
  • Carvalho PEP, Veiga TMA, Simões E Silva AC, et al. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. Clin Res Cardiol. 2023;112(8):1044–1055. doi: 10.1007/s00392-022-02148-2.
  • Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568–574. doi: 10.1038/s41591-021-01659-1.
  • Boorsma EM, Beusekamp JC, Ter Maaten JM, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. Eur J Heart Fail. 2021;23(1):68–78. doi: 10.1002/ejhf.2066.
  • Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement. JAMA Netw Open. 2020;3(10):e2019209. doi: 10.1001/jamanetworkopen.2020.19209.
  • Thiele K, Rau M, Hartmann NK, et al. Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. ESC Heart Fail. 2022;9(4):2233–2238. doi: 10.1002/ehf2.13955.
  • Nourbakhsh N, Singh P. Role of renal oxygenation and mitochondrial function in the pathophysiology of acute kidney injury. Nephron Clin Pract. 2014;127(1-4):149–152. doi: 10.1159/000363545.
  • Zhou S, Zhang Y, Wang T, et al. Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function. Diabetes Metab. 2021;47(5):101274. doi: 10.1016/j.diabet.2021.101274.
  • Menne J, Dumann E, Haller H, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systemic review and meta-analysis. PLoS Med. 2019;16(12):e1002983. doi: 10.1371/journal.pmed.1002983.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.